Cargando…

Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma

Objective: To assess the value of microbubble contrast agent SonoVue in the thorough preoperative lymphatic mapping of patients with thyroid carcinoma, including the lymphatic drainage region, the detection of sentinel lymph node (SLN), and the diagnosis of lymph node metastasis (LNM). Materials and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei, Dong, Bingwan, Jiang, Liu, Zhang, Jixin, Chen, Luzeng, Li, Tiancheng, Shao, Yuhong, Sun, Xiuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773067/
https://www.ncbi.nlm.nih.gov/pubmed/36568294
http://dx.doi.org/10.3389/fbioe.2022.1077145
_version_ 1784855117741162496
author Chen, Lei
Dong, Bingwan
Jiang, Liu
Zhang, Jixin
Chen, Luzeng
Li, Tiancheng
Shao, Yuhong
Sun, Xiuming
author_facet Chen, Lei
Dong, Bingwan
Jiang, Liu
Zhang, Jixin
Chen, Luzeng
Li, Tiancheng
Shao, Yuhong
Sun, Xiuming
author_sort Chen, Lei
collection PubMed
description Objective: To assess the value of microbubble contrast agent SonoVue in the thorough preoperative lymphatic mapping of patients with thyroid carcinoma, including the lymphatic drainage region, the detection of sentinel lymph node (SLN), and the diagnosis of lymph node metastasis (LNM). Materials and methods: 55 patients with 62 thyroid malignancies proved by surgical pathology (59 papillary thyroid carcinomas and three medullary thyroid carcinomas) who underwent preoperative lymphatic contrast-enhanced ultrasound (LCEUS) with microbubble contrast agent SonoVue were enrolled. All LNM were confirmed by pathology. The location of thyroid lesions, ultrasonic features of lymph nodes, lymphatic drainage region, and detection of SLN were assessed. The diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value and accuracy) of different parameters for the LNM diagnosis was calculated. Results: SonoVue effectively demonstrated the lymphatic drainage region for all enrolled thyroid carcinomas. The most common lymphatic drainage region for thyroid carcinomas was region VI (93.55%), followed by region III (62.90%), region IV (48.39%) and region II (4.84%). When divided by the lesion location, the most common lymphatic drainage regions for the nodule in isthmus, superior lobe and inferior lobe of the thyroid were region VI, region III, and region VI respectively. SLN was detected in 96.77% (60/62) of cases. The two cases without SLN demonstration had pathologically proven LNM. The most common sonographic sign of LNM was perfusion defect (54.17%). The diagnostic accuracy of SonoVue in central and lateral compartment LNM was 86.67% and 91.67%, respectively. Conclusion: Microbubble contrast agent SonoVue is a valuable imaging contrast medium for thorough preoperative lymphatic mapping in patients with thyroid carcinoma, including the lymphatic drainage region, the detection of SLN, and the diagnosis of LNM. LCEUS with SonoVue alone has limitations of false negatives when there is lymphatic vessel obstruction and may need to be combined with other ultrasound modalities.
format Online
Article
Text
id pubmed-9773067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97730672022-12-23 Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma Chen, Lei Dong, Bingwan Jiang, Liu Zhang, Jixin Chen, Luzeng Li, Tiancheng Shao, Yuhong Sun, Xiuming Front Bioeng Biotechnol Bioengineering and Biotechnology Objective: To assess the value of microbubble contrast agent SonoVue in the thorough preoperative lymphatic mapping of patients with thyroid carcinoma, including the lymphatic drainage region, the detection of sentinel lymph node (SLN), and the diagnosis of lymph node metastasis (LNM). Materials and methods: 55 patients with 62 thyroid malignancies proved by surgical pathology (59 papillary thyroid carcinomas and three medullary thyroid carcinomas) who underwent preoperative lymphatic contrast-enhanced ultrasound (LCEUS) with microbubble contrast agent SonoVue were enrolled. All LNM were confirmed by pathology. The location of thyroid lesions, ultrasonic features of lymph nodes, lymphatic drainage region, and detection of SLN were assessed. The diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value and accuracy) of different parameters for the LNM diagnosis was calculated. Results: SonoVue effectively demonstrated the lymphatic drainage region for all enrolled thyroid carcinomas. The most common lymphatic drainage region for thyroid carcinomas was region VI (93.55%), followed by region III (62.90%), region IV (48.39%) and region II (4.84%). When divided by the lesion location, the most common lymphatic drainage regions for the nodule in isthmus, superior lobe and inferior lobe of the thyroid were region VI, region III, and region VI respectively. SLN was detected in 96.77% (60/62) of cases. The two cases without SLN demonstration had pathologically proven LNM. The most common sonographic sign of LNM was perfusion defect (54.17%). The diagnostic accuracy of SonoVue in central and lateral compartment LNM was 86.67% and 91.67%, respectively. Conclusion: Microbubble contrast agent SonoVue is a valuable imaging contrast medium for thorough preoperative lymphatic mapping in patients with thyroid carcinoma, including the lymphatic drainage region, the detection of SLN, and the diagnosis of LNM. LCEUS with SonoVue alone has limitations of false negatives when there is lymphatic vessel obstruction and may need to be combined with other ultrasound modalities. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9773067/ /pubmed/36568294 http://dx.doi.org/10.3389/fbioe.2022.1077145 Text en Copyright © 2022 Chen, Dong, Jiang, Zhang, Chen, Li, Shao and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Chen, Lei
Dong, Bingwan
Jiang, Liu
Zhang, Jixin
Chen, Luzeng
Li, Tiancheng
Shao, Yuhong
Sun, Xiuming
Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title_full Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title_fullStr Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title_full_unstemmed Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title_short Microbubble contrast agent SonoVue: An efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
title_sort microbubble contrast agent sonovue: an efficient medium for the preoperative lymphatic mapping of thyroid carcinoma
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773067/
https://www.ncbi.nlm.nih.gov/pubmed/36568294
http://dx.doi.org/10.3389/fbioe.2022.1077145
work_keys_str_mv AT chenlei microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT dongbingwan microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT jiangliu microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT zhangjixin microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT chenluzeng microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT litiancheng microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT shaoyuhong microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma
AT sunxiuming microbubblecontrastagentsonovueanefficientmediumforthepreoperativelymphaticmappingofthyroidcarcinoma